This Pennsylvania bill requires most health insurance plans to cover vaginal estrogen when used to treat menopausal symptoms or prevent urinary tract infections. The law mandates that insurers include FDA-approved drugs, devices, and combination products for this treatment, though they may still apply standard rules regarding medical necessity and patient cost-sharing. Coverage applies to new or renewed policies starting 90 days after the bill takes effect, with specific timelines for plans that do not need to file rates or forms with the state.
HB 1244 requires health insurance policies and government health programs in Pennsylvania to cover pelvic floor therapy and related treatments for pelvic floor dysfunction. This includes services like biofeedback, trigger point therapy, electrical stimulation, and postoperative care for prostatectomies, hysterectomies, and postpartum assessments. The coverage applies to policies issued or renewed after the bill's effective date, though insurers may still apply medical necessity standards and cost-sharing requirements. The bill directly affects all health insurance companies and government health programs (such as Medicaid) operating under Pennsylvania's insurance law.
This bill requires Medicaid programs and private health insurance plans to cover bone density screenings, preventive care, and treatments for osteoporosis specifically linked to menopause. It directly affects postmenopausal women, particularly those with low income who rely on Medicaid, by ensuring access to these services without cost barriers. The key provision mandates that both public medical assistance programs and private insurers include these osteoporosis-related services in standard coverage. This expands existing coverage to explicitly address menopause-related bone health needs.
HB 1346 amends Pennsylvania's Insurance Company Law to mandate coverage for menopause treatments in health insurance policies. This bill requires health insurance policies offered or renewed in the Commonwealth to provide coverage for both hormonal and non-hormonal treatments for menopausal symptoms. The required coverage includes FDA-approved drugs, devices, behavioral therapy, and treatments for menopause induced by a hysterectomy. This ensures individuals in Pennsylvania experiencing menopause or related symptoms have access to covered treatments, subject to the standard terms and conditions of their health insurance policy.
HB 1460, the Health System Protection Act, requires health care entities (like hospitals and clinics) and certain investors (such as private equity firms) to obtain pre-approval from Pennsylvania's Department of Health and Attorney General before completing major transactions. This applies to sales of assets worth $10 million or more, ownership changes, or large financial distributions that could affect competition, costs, or access to care. The law prohibits transactions deemed "against the public interest," such as those reducing competition, raising prices, or limiting services in rural or low-income areas. Health care entities must either file a notification with a waiting period or get written approval before proceeding.
This bill establishes legal protections for music therapy by requiring anyone who identifies as a music therapist to hold a valid certification from the Certification Board for Music Therapists. It prohibits unlicensed individuals from claiming to be music therapists, using specific credentials like "MT-BC," or implying they are qualified to provide clinical music therapy services. While the law allows professionals to use music in their general work, it strictly forbids them from representing themselves as certified music therapists without the proper credential. Violations of these rules are classified as third-degree misdemeanors and are also treated as unfair trade practices under state consumer protection laws.
This bill amends Pennsylvania's Insurance Company Law to update definitions and provisions related to health insurance coverage. It clarifies how certain government health programs are defined for insurance policies, specifically regarding prescription drug coverage and continuation of coverage for employees who lose their jobs. The legislation also updates the legal definition of a hospital to include facilities operating alcoholism or drug addiction treatment programs and establishes a Long-Term Care Partnership Program to help individuals manage future long-term care costs.
HB 2427 amends Pennsylvania's Insurance Company Law to regulate how insurers cover drugs for stage four, advanced metastatic cancer. The bill prohibits insurance policies from requiring patients to fail a different medication or prove a history of failure before approving coverage for a new drug, provided the drug is FDA-approved and aligns with current clinical best practices. This legislation also repeals the previous Fair Access to Cancer Treatment Law while ensuring that all existing rules, contracts, and decisions made under that law remain in effect.
HB 836 prohibits Pennsylvania from interfering with the use of medically appropriate assisted reproductive technology (ART), such as in vitro fertilization (IVF), ensuring individuals can access these services without state restrictions. The bill defines ART to include specific fertility procedures and requires that any new state laws must comply with this protection unless explicitly exempted by the legislature. It takes effect immediately, providing direct safeguards for individuals seeking ART services and healthcare providers offering them.
This bill creates a new chapter in Pennsylvania law to regulate medical devices by banning specific toxic chemicals known as ortho-phthalates, with a primary focus on DEHP. The legislation targets manufacturers of intravenous solution containers and tubing, which currently use these chemicals to make plastic flexible. By prohibiting the intentional addition of these substances, the bill aims to prevent the chemicals from leaching into patient fluids and reducing the effectiveness of cancer treatments. The law is based on findings that these compounds can act as endocrine disruptors, potentially harming reproductive health and contributing to drug resistance in cancer cells.
